SOURCE: 3-V Biosciences

3-V Biosciences

April 07, 2015 05:30 ET

3-V Biosciences Announces Three Poster Presentations at the 2015 AACR Annual Meeting

MENLO PARK, CA--(Marketwired - Apr 7, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the upcoming presentation of three abstracts at the American Association for Cancer Research (AACR) annual meeting. The conference takes place in Philadelphia, PA on April 18-22, 2015. 
Details for the three poster presentations are as follows:

  • Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640.
    Abstract # CT203 -- Monday, April 20, 2015, 8:00AM - 12:00PM -- Location: section 25
  • Biomarker and PK/PD Analyses of First in Class FASN Inhibitor TVB-2640 in a First-in-Human Phase 1 Study in Solid Tumor Patients
    Abstract # 2675 -- Monday, April 20, 2015, 1:00PM - 5:00PM -- Location: section 32
  • Discovery of Tumor Types Highly Susceptible to FASN Inhibition and Biomarker Candidates for Clinical Analysis
    Abstract # 4446 -- Tuesday, April 21, 2015, 1:00PM - 5:00PM -- Location: section 30

The meeting abstracts can be viewed online through the AACR website at www.aacr.org.

About TVB-2640
TVB-2640 is an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. FASN, an enzyme responsible for the synthesis of palmitic acid (palmitate), plays a key role in tumor metabolism, lipid signaling and tumor cell survival. FASN over-expression is associated with aggressive disease and poor prognosis in a number of solid tumors. TVB-2640 is the first FASN inhibitor to enter human clinical trials.

About 3-V Biosciences
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V's antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact Information

  • Investor Relations Contact:
    Jamien Jones
    Blueprint Life Science Group
    Telephone: 415.375.3340 Ext. 103
    Email Contact